NRx Pharma: Data Safety Monitoring Board Finds No New Safety Concerns In ACTIV-3b Trial

(RTTNews) - NRx Pharmaceuticals (NRXP) said the Independent Data Safety Monitoring Board found no new safety concerns in the ACTIV-3b Critical Care phase 3 study, after reviewing 231 patients, and recommended continued enrollment. ACTIV-3b is a randomized, placebo-controlled trial testing ZYESAMI and remdesivir - alone and in combination - in hospitalized patients with acute respiratory failure due to COVID-19 who require high-flow supplemental oxygen.

"With this second independent safety analysis in the ACTIV-3b trial, the safety database on ZYESAMI has grown to more than 500 patients. So far, there have been no reports of unexpected, drug-related serious adverse events," said Jonathan Javitt, CEO of NRx.